Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

No evidence for shared etiology in two demyelinative disorders, MS and PLOSL.

Sulonen AM, Kallio SP, Ellonen P, Suvela M, Elovaara I, Koivisto K, Pirttilä T, Reunanen M, Tienari PJ, Palotie A, Peltonen L, Saarela J.

J Neuroimmunol. 2009 Jan 3;206(1-2):86-90. doi: 10.1016/j.jneuroim.2008.10.005.

2.

The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.

Klünemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, Peltonen L, Paloneva J.

Neurology. 2005 May 10;64(9):1502-7.

PMID:
15883308
3.

DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.

Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L.

J Exp Med. 2003 Aug 18;198(4):669-75.

4.

Transcript profiles of dendritic cells of PLOSL patients link demyelinating CNS disorders with abnormalities in pathways of actin bundling and immune response.

Kiialainen A, Veckman V, Saharinen J, Paloneva J, Gentile M, Hakola P, Hemelsoet D, Ridha B, Kopra O, Julkunen I, Peltonen L.

J Mol Med (Berl). 2007 Sep;85(9):971-83.

PMID:
17530208
5.

Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease.

Sasaki A, Kakita A, Yoshida K, Konno T, Ikeuchi T, Hayashi S, Matsuo H, Shioda K.

Neurogenetics. 2015 Oct;16(4):265-76. doi: 10.1007/s10048-015-0451-3.

PMID:
26001891
6.

Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS.

Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L.

Neurobiol Dis. 2005 Mar;18(2):314-22.

PMID:
15686960
7.

Fine-scale mapping of a novel dementia gene, PLOSL, by linkage disequilibrium.

Pekkarinen P, Kestilä M, Paloneva J, Terwillign J, Varilo T, Järvi O, Hakola P, Peltonen L.

Genomics. 1998 Dec 1;54(2):307-15.

PMID:
9828133
8.

Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia.

Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J.

Eur J Neurosci. 2004 Nov;20(10):2617-28.

PMID:
15548205
9.

Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype.

Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L.

Am J Hum Genet. 2002 Sep;71(3):656-62. Erratum in: Am J Hum Genet. 2003 Jan;72(1):225..

10.

DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response.

Zhong L, Chen XF, Zhang ZL, Wang Z, Shi XZ, Xu K, Zhang YW, Xu H, Bu G.

J Biol Chem. 2015 Jun 19;290(25):15866-77. doi: 10.1074/jbc.M115.645986.

11.

A novel compound heterozygous mutation in the DAP12 gene in a patient with Nasu-Hakola disease.

Kuroda R, Satoh J, Yamamura T, Anezaki T, Terada T, Yamazaki K, Obi T, Mizoguchi K.

J Neurol Sci. 2007 Jan 15;252(1):88-91.

PMID:
17125796
12.

TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function.

Humphrey MB, Daws MR, Spusta SC, Niemi EC, Torchia JA, Lanier LL, Seaman WE, Nakamura MC.

J Bone Miner Res. 2006 Feb;21(2):237-45.

13.

Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.

Paloneva J, Kestilä M, Wu J, Salminen A, Böhling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P, Lanier LL, Timonen T, Peltonen L.

Nat Genet. 2000 Jul;25(3):357-61.

PMID:
10888890
14.

Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.

Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, da Silva Júnior JP, Neto Evaldo S, Poffo MA, Walz R, Carlotti Júnior CG, Sakamoto AC.

Cell Mol Neurobiol. 2004 Feb;24(1):1-24. Review.

PMID:
15049507
15.

TREM2 in CNS homeostasis and neurodegenerative disease.

Painter MM, Atagi Y, Liu CC, Rademakers R, Xu H, Fryer JD, Bu G.

Mol Neurodegener. 2015 Sep 4;10:43. doi: 10.1186/s13024-015-0040-9. Review.

16.

Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage.

Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J.

J Biol Chem. 2013 Nov 15;288(46):33027-36. doi: 10.1074/jbc.M113.517540.

17.
18.

The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.

Bianchin MM, Lima JE, Natel J, Sakamoto AC.

Neurology. 2006 Feb 28;66(4):615-6; author reply 615-6. No abstract available.

PMID:
16505336
19.

What happens to microglial TREM2 in Alzheimer's disease: Immunoregulatory turned into immunopathogenic?

Lue LF, Schmitz C, Walker DG.

Neuroscience. 2015 Aug 27;302:138-50. doi: 10.1016/j.neuroscience.2014.09.050. Review.

PMID:
25281879
20.

C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation.

Solje E, Hartikainen P, Valori M, Vanninen R, Tiihonen J, Hakola P, Tienari PJ, Remes AM.

Neurobiol Aging. 2014 Jul;35(7):1780.e13-7. doi: 10.1016/j.neurobiolaging.2014.01.149.

PMID:
24612676

Supplemental Content

Support Center